oncotomskСибирский онкологический журналSiberian journal of oncology1814-48612312-3168Tomsk National Research Medical Сепtеr of the Russian Academy of Sciences10.21294/1814-4861-2022-21-3-33-41oncotomsk-2161Research ArticleКЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯCLINICAL STUDIESПовреждение ДНК в мононуклеарных клетках периферической крови у пациентов c меланомойDNA damage in peripheral blood mononuclear cells in patients with melanomahttps://orcid.org/0000-0002-0882-6697ЦырлинаЕ. В.TsyrlinaE. V.

Цырлина Евгения Владимировна, кандидат медицинских наук, ведущий научный сотрудник

197758, г. Санкт-Петербург, пос. Песочный, ул. Ленинградская, 68

Evgenia V. Tsyrlina, MD, PhD, Leading Researcher

68, Leningradskaya St., 197758, St. Petersburg

evg.tsyrlina@gmail.comhttps://orcid.org/0000-0001-5558-5366ПорошинаТ. Е.PoroshinaT. E.

Порошина Татьяна Евгеньевна, кандидат биологических наук, биолог

6197758, г. Санкт-Петербург, пос. Песочный, ул. Ленинградская, 68

Tatyana E. Poroshina, PhD, Biologist

68, Leningradskaya St., 197758, St. Petersburg

https://orcid.org/0000-0002-4215-2948ВасильевД. А.VasilievD. A.

Васильев Дмитрий Алексеевич, кандидат медицинских наук, старший научный сотрудник

197758, г. Санкт-Петербург, пос. Песочный, ул. Ленинградская, 68

Dmitry A. Vasiliev, MD, PhD, Senior Researcher

68, Leningradskaya St., 197758, St. Petersburg

https://orcid.org/0000-0003-1639-2443ЗиновьевГ. В.ZinovievG. V.

Зиновьев Григорий Владимирович, кандидат медицинских наук, заведующий хирургическим отделением опухолей костей, мягких тканей и кожи

197758, г. Санкт-Петербург, пос. Песочный, ул. Ленинградская, 68

Grigory V. Zinoviev, MD, PhD, Head of Surgical Department of Bone, Soft Tissue and Skin Tumors

68, Leningradskaya St., 197758, St. Petersburg

https://orcid.org/0000-0003-3172-2201ГафтонГ. И.GaftonG. I.

Гафтон Георгий Иванович, доктор медицинских наук, заведующий научным отделением

197758, г. Санкт-Петербург, пос. Песочный, ул. Ленинградская, 68

Georgy I. Gafton, MD, DSc, Head of Scientific Department

68, Leningradskaya St., 197758, St. Petersburg

https://orcid.org/0000-0002-5112-3372БерштейнЛ. М.BersteinL. M.

Берштейн Лев Михайлович, доктор медицинских наук, профессор

197758, г. Санкт-Петербург, пос. Песочный, ул. Ленинградская, 68

Lev M. Bershtein, MD, DSc, Professor

68, Leningradskaya St., 197758, St. Petersburg

ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Петрова» Минздрава РоссииРоссияN.N. Petrov National Medical Oncology Research Center of the Ministry of Health of RussiaRussian Federation2022290620222133341Copyright © Цырлина Е.В., Порошина Т.Е., Васильев Д.А., Зиновьев Г.В., Гафтон Г.И., Берштейн Л.М., 20222022Цырлина Е.В., Порошина Т.Е., Васильев Д.А., Зиновьев Г.В., Гафтон Г.И., Берштейн Л.М.Tsyrlina E.V., Poroshina T.E., Vasiliev D.A., Zinoviev G.V., Gafton G.I., Berstein L.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.siboncoj.ru/jour/article/view/2161Введение

Введение. Заболеваемость злокачественной меланомой и ее уровень смертности в последние десятилетия неуклонно растут, что делает актуальным разработку дополнительных маркеров диагностики этой патологии.

Цель исследования – оценить, сопровождается ли развитие меланомы до проведения какого-либо лечения изменениями на уровне организма и, в частности, повреждением ДНК в мононуклеарных клетках периферической крови пациентов.

Материал и методы

Материал и методы. У 93 пациентов, поступивших в ФГБУ «НМИЦ онкологии им Н.Н.Петрова» для оперативного лечения меланомы кожи, и 118 здоровых лиц в качестве группы сравнения методом «комет» была исследована степень повреждения ДНК в мононуклеарных клетках периферической крови. В группу пациентов было включено 26 мужчин и 67 женщин с опухолями T1c-2a-b-3a-b-4a-bN0-1,M0-1 стадии. В процессе анализа все больные были разделены в зависимости от сроков обследования на две группы: 1-я группа – 45 пациентов (13 мужчин и 32 женщины), обследованных до каких-либо лечебных вмешательств; 2-я группа – 48 пациентов (13 мужчин и 35 женщин), предварительно получивших нерадикальное лечение в виде биопсии меланомы.

Результаты

Результаты. Показано, что степень повреждения ДНК в мононуклеарных клетках периферической крови, выявленная методом «комет», у пациентов с меланомой достоверно выше, чем в группе сравнения. Причем это повышение было близким по величине как у пациентов с первичной опухолью до начала каких-либо лечебных воздействий, так и у тех, кому предварительно была сделана попытка нерадикального удаления новообразования. Выявлена определенная зависимость степени повреждения ДНК в мононуклеараных клетках периферической крови от морфологической характеристики опухоли: так, при расчете корреляций по Спирмену все показатели, определяющие повреждение ДНК, хотя и слабо, но положительно коррелировали с толщиной меланомы по индексу Бреслоу, а процент ДНК в комете и момент хвоста кометы коррелировали и со стадией заболевания.

Заключение

Заключение. Развитие меланомы кожи сопровождается повышением степени повреждения ДНК в мононуклеарных клетках периферической крови. Степень повреждения ДНК в мононуклеарных клетках периферической крови отражает изменения, происходящие в организме пациента под влиянием опухолевого процесса, что, возможно, позволит использовать этот показатель как дополнительный критерий диагностики и агрессивности меланомы.

Introduction. The incidence and mortality of malignant melanoma have increased steadily over the last decades; therefore, the development of novel diagnostic markers for malignant melanoma is of great importance. The purpose of the study was to assess whether the development of melanoma before any treatment is accompanied by the body changes and, in particular, DNA damage in the mononuclear cells of the peripheral blood of patients. Material and Methods. In 93 patients (26 men and 67 women) admitted to the N.N. Petrov National Medical Research Center of Oncology for surgical treatment of stage T1c-2a-b-3a-b4a-bN0-1 cutaneous malignant melanoma, and in 118 healthy people as a comparison group, the level of damage to DNA in peripheral blood mononuclear cells was studied using the “comet” method. All patients were divided into two groups: group 1 included 45 patients (13 men and 32 women) who were examined before a decision on treatment was made and group 2 consisted of 48 patients (13 men and 35 women) who previously underwent excision biopsy for melanoma. Results. The level of DNA damage in peripheral blood mononuclear cells, assessed by the comet assay, was found to be signifcantly higher in patients with melanoma than in the comparison group. Moreover, the increase in the level of DNA damage was similar both in patients with a primary tumor before starting any treatment and in those who previously underwent excision biopsy for melanoma. The relationship between the level of DNA damage in peripheral blood mononuclear cells and the morphological characteristics of the tumor cells was revealed. The Spearman correlation analysis showed that all parameters that determined DNA damage positively correlated with the thickness of melanoma according to the Breslow’s depth, and the percentage of DNA in the comet and the comet tail moment correlated with the stage of the disease. Conclusion. The development of cutaneous melanoma is accompanied by an increase in the level of DNA damage in peripheral blood mononuclear cells. The level of DNA damage in peripheral blood mononuclear cells refects the changes that occur in the patient’s body under the infuence of the tumor process, which may allow using this indicator as an additional criterion for the diagnosis and aggressiveness of melanoma.

меланомаповреждение ДНкмононуклеарные клетки периферической кровиметод «комет»melanomaDNA damagemononuclear cellscomet methodReferencesLeiter U., Keim U., Garbe C. Epidemiology of Skin Cancer: Update 2019. Adv Exp Med Biol. 2020; 1268: 123–39. doi: 10.1007/978-3-030- 46227-7_6.Leiter U., Keim U., Garbe C. Epidemiology of Skin Cancer: Update 2019. Adv Exp Med Biol. 2020; 1268: 123–39. doi: 10.1007/978-3-030- 46227-7_6.Pilié P.G., Tang C., Mills G.B., Yap T.A. State-of-the-art strategies for targeting the DNA damage response in cancer. Nat Rev Clin Oncol. 2019; 16(2): 81–104. doi: 10.1038/s41571-018-0114-z.Pilié P.G., Tang C., Mills G.B., Yap T.A. State-of-the-art strategies for targeting the DNA damage response in cancer. Nat Rev Clin Oncol. 2019; 16(2): 81–104. doi: 10.1038/s41571-018-0114-z.Kuchařová M., Hronek M., Rybáková K., Zadák Z., Štětina R., Josková V., Patková A. Comet assay and its use for evaluating oxidative DNA damage in some pathological states. Physiol Res. 2019; 68(1): 1–15. doi: 10.33549/physiolres.933901.Kuchařová M., Hronek M., Rybáková K., Zadák Z., Štětina R., Josková V., Patková A. Comet assay and its use for evaluating oxidative DNA damage in some pathological states. Physiol Res. 2019; 68(1): 1–15. doi: 10.33549/physiolres.933901.Burrell R.A., McClelland S.E., Endesfelder D., Groth P., Weller M.C., Shaikh N., Domingo E., Kanu N., Dewhurst S.M., Gronroos E., Chew S.K., Rowan A.J., Schenk A., Sheffer M., Howell M., Kschischo M., Behrens A., Helleday T., Bartek J., Tomlinson I.P., Swanton C. Replication stress links structural and numerical cancer chromosomal instability. Nature. 2013; 494 (7438): 492–6.Burrell R.A., McClelland S.E., Endesfelder D., Groth P., Weller M.C., Shaikh N., Domingo E., Kanu N., Dewhurst S.M., Gronroos E., Chew S.K., Rowan A.J., Schenk A., Sheffer M., Howell M., Kschischo M., Behrens A., Helleday T., Bartek J., Tomlinson I.P., Swanton C. Replication stress links structural and numerical cancer chromosomal instability. Nature. 2013; 494 (7438): 492–6.Wilhelm T., Olziersky A.M., Harry D., De Sousa F., Vassal H., Eskat A., Meraldi P. Mild replication stress causes chromosome missegregation via premature centriole disengagement. Nat Commun. 2019; 10(1): 3585. doi: 10.1038/s41467-019-11584-0.Wilhelm T., Olziersky A.M., Harry D., De Sousa F., Vassal H., Eskat A., Meraldi P. Mild replication stress causes chromosome missegregation via premature centriole disengagement. Nat Commun. 2019; 10(1): 3585. doi: 10.1038/s41467-019-11584-0.Lugović L., Situm M., Kos L. Malignant melanoma--future prospects. Acta Dermatovenerol Croat. 2005; 13(1): 36–43.Lugović L., Situm M., Kos L. Malignant melanoma--future prospects. Acta Dermatovenerol Croat. 2005; 13(1): 36–43.Valavanidis A., Vlachogianni T., Fiotakis C. 8-hydroxy-2’ -deoxyguanosine (8-OHdG): A critical biomarker of oxidative stress and carcinogenesis. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2009; 27(2): 120–39. doi: 10.1080/10590500902885684.Valavanidis A., Vlachogianni T., Fiotakis C. 8-hydroxy-2’ -deoxyguanosine (8-OHdG): A critical biomarker of oxidative stress and carcinogenesis. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2009; 27(2): 120–39. doi: 10.1080/10590500902885684.Khosla L., Gong S., Weiss J.P., Birder L.A. Oxidative Stress Biomarkers in Age-Related Lower Urinary Tract Disorders: A Systematic Review. Int Neurourol J. 2022; 26(1): 3–19. doi: 10.5213/inj.2142188.094.Khosla L., Gong S., Weiss J.P., Birder L.A. Oxidative Stress Biomarkers in Age-Related Lower Urinary Tract Disorders: A Systematic Review. Int Neurourol J. 2022; 26(1): 3–19. doi: 10.5213/inj.2142188.094.Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell. 2011; 144(5): 646–74. doi: 10.1016/j.cell.2011.02.013.Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell. 2011; 144(5): 646–74. doi: 10.1016/j.cell.2011.02.013.Pearl L.H., Schierz A.C., Ward S.E., Al-Lazikani B., Pearl F.M. Therapeutic opportunities within the DNA damage response. Nat Rev Cancer. 2015; 15(3): 166–80. doi: 10.1038/nrc3891.Pearl L.H., Schierz A.C., Ward S.E., Al-Lazikani B., Pearl F.M. Therapeutic opportunities within the DNA damage response. Nat Rev Cancer. 2015; 15(3): 166–80. doi: 10.1038/nrc3891.Milic M., Frustaci A., Del Bufalo A., Sánchez-Alarcón J., ValenciaQuintana R., Russo P., Bonassi S. DNA damage in non-communicable diseases: A clinical and epidemiological perspective. Mutat Res. 2015; 776: 118–27. doi: 10.1016/j.mrfmmm.2014.11.009.Milic M., Frustaci A., Del Bufalo A., Sánchez-Alarcón J., ValenciaQuintana R., Russo P., Bonassi S. DNA damage in non-communicable diseases: A clinical and epidemiological perspective. Mutat Res. 2015; 776: 118–27. doi: 10.1016/j.mrfmmm.2014.11.009.Møller P., Stopper H., Collins A.R. Measurement of DNA damage with the comet assay in high-prevalence diseases: current status and future directions. Mutagenesis. 2020; 35(1): 5–18. doi: 10.1093/mutage/ gez018.Møller P., Stopper H., Collins A.R. Measurement of DNA damage with the comet assay in high-prevalence diseases: current status and future directions. Mutagenesis. 2020; 35(1): 5–18. doi: 10.1093/mutage/ gez018.Azqueta A., Ladeira C., Giovannelli L., Boutet-Robinet E., Bonassi S., Neri M., Gajski G., Duthie S., Del Bo’ C., Riso P., Koppen G., Basaran N., Collins A., Møller P. Application of the comet assay in human biomonitoring: An hCOMET perspective. Mutat Res Rev Mutat Res. 2020; 783. doi: 10.1016/j.mrrev.2019.108288.Azqueta A., Ladeira C., Giovannelli L., Boutet-Robinet E., Bonassi S., Neri M., Gajski G., Duthie S., Del Bo’ C., Riso P., Koppen G., Basaran N., Collins A., Møller P. Application of the comet assay in human biomonitoring: An hCOMET perspective. Mutat Res Rev Mutat Res. 2020; 783. doi: 10.1016/j.mrrev.2019.108288.Sykora P., Witt K.L., Revanna P., Smith-Roe S.L., Dismukes J., Lloyd D.G., Engelward B.P., Sobol R.W. Next generation high throughput DNA damage detection platform for genotoxic compound screening. Sci Rep. 2018; 8(1): 2771. doi: 10.1038/s41598-018-20995-w.Sykora P., Witt K.L., Revanna P., Smith-Roe S.L., Dismukes J., Lloyd D.G., Engelward B.P., Sobol R.W. Next generation high throughput DNA damage detection platform for genotoxic compound screening. Sci Rep. 2018; 8(1): 2771. doi: 10.1038/s41598-018-20995-w.Lawrence M.S., Stojanov P., Mermel C.H., Robinson J.T., Garraway L.A., Golub T.R., Meyerson M., Gabriel S.B., Lander E.S., Getz G. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature. 2014; 505(7484): 495–501.Lawrence M.S., Stojanov P., Mermel C.H., Robinson J.T., Garraway L.A., Golub T.R., Meyerson M., Gabriel S.B., Lander E.S., Getz G. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature. 2014; 505(7484): 495–501.Mouw K.W., Goldberg M.S., Konstantinopoulos P.A., D’Andrea A.D. DNA Damage and Repair Biomarkers of Immunotherapy Response. Cancer Discov. 2017; 7(7): 675–93. doi: 10.1158/2159-8290.CD-17-0226.Mouw K.W., Goldberg M.S., Konstantinopoulos P.A., D’Andrea A.D. DNA Damage and Repair Biomarkers of Immunotherapy Response. Cancer Discov. 2017; 7(7): 675–93. doi: 10.1158/2159-8290.CD-17-0226.Perkhofer L., Gout J., Roger E., Kude de Almeida F., Baptista Simões C., Wiesmüller L., Seufferlein T., Kleger A. DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectives. Gut. 2021; 70(3): 606–17. doi: 10.1136/gutjnl-2019-319984.Perkhofer L., Gout J., Roger E., Kude de Almeida F., Baptista Simões C., Wiesmüller L., Seufferlein T., Kleger A. DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectives. Gut. 2021; 70(3): 606–17. doi: 10.1136/gutjnl-2019-319984.Duijf P.H.G., Nanayakkara D., Nones K., Srihari S., Kalimutho M., Khanna K.K. Mechanisms of Genomic Instability in Breast Cancer. Trends Mol Med. 2019; 25(7): 595–611. doi: 10.1016/j.molmed.2019.04.004.Duijf P.H.G., Nanayakkara D., Nones K., Srihari S., Kalimutho M., Khanna K.K. Mechanisms of Genomic Instability in Breast Cancer. Trends Mol Med. 2019; 25(7): 595–611. doi: 10.1016/j.molmed.2019.04.004.Galardi F., Oakman C., Truglia M.C., Cappadona S., Biggeri A., Grisotto L., Giovannelli L., Bessi S., Giannini A., Biganzoli L., Santarpia L., Di Leo A. Inter- and intra-tumoral heterogeneity in DNA damage evaluated by comet assay in early breast cancer patients. Breast. 2012; 21(3): 336–42. doi: 10.1016/j.breast.2012.02.007.Galardi F., Oakman C., Truglia M.C., Cappadona S., Biggeri A., Grisotto L., Giovannelli L., Bessi S., Giannini A., Biganzoli L., Santarpia L., Di Leo A. Inter- and intra-tumoral heterogeneity in DNA damage evaluated by comet assay in early breast cancer patients. Breast. 2012; 21(3): 336–42. doi: 10.1016/j.breast.2012.02.007.Cortés-Gutiérrez E.I., Hernández-Garza F., García-Pérez J.O., Dávila-Rodríguez M.I., Aguado-Barrera M.E., Cerda-Flores R.M. Evaluation of DNA single and double strand breaks in women with cervical neoplasia based on alkaline and neutral comet assay techniques. J Biomed Biotechnol. 2012. doi: 10.1155/2012/385245.Cortés-Gutiérrez E.I., Hernández-Garza F., García-Pérez J.O., Dávila-Rodríguez M.I., Aguado-Barrera M.E., Cerda-Flores R.M. Evaluation of DNA single and double strand breaks in women with cervical neoplasia based on alkaline and neutral comet assay techniques. J Biomed Biotechnol. 2012. doi: 10.1155/2012/385245.Burrell R.A., McClelland S.E., Endesfelder D., Groth P., Weller M.C., Shaikh N., Domingo E., Kanu N., Dewhurst S.M., Gronroos E., Chew S.K., Rowan A.J., Schenk A., Sheffer M., Howell M., Kschischo M., Behrens A., Helleday T., Bartek J., Tomlinson I.P., Swanton C. Replication stress links structural and numerical cancer chromosomal instability. Nature. 2013; 494(7438): 492–6.Burrell R.A., McClelland S.E., Endesfelder D., Groth P., Weller M.C., Shaikh N., Domingo E., Kanu N., Dewhurst S.M., Gronroos E., Chew S.K., Rowan A.J., Schenk A., Sheffer M., Howell M., Kschischo M., Behrens A., Helleday T., Bartek J., Tomlinson I.P., Swanton C. Replication stress links structural and numerical cancer chromosomal instability. Nature. 2013; 494(7438): 492–6.Wilhelm T., Said M., Naim V. DNA Replication Stress and Chromosomal Instability: Dangerous Liaisons. Genes (Basel). 2020; 11(6): 642. doi: 10.3390/genes11060642.Wilhelm T., Said M., Naim V. DNA Replication Stress and Chromosomal Instability: Dangerous Liaisons. Genes (Basel). 2020; 11(6): 642. doi: 10.3390/genes11060642.Fikrova P., Stetina R., Hrnciarik M., Hrnciarikova D., Hronek M., Zadak Z. DNA crosslinks, DNA damage and repair in peripheral blood lymphocytes of non-small cell lung cancer patients treated with platinum derivatives. Oncol Rep. 2014; 31(1): 391–6. doi: 10.3892/or.2013.2805.Fikrova P., Stetina R., Hrnciarik M., Hrnciarikova D., Hronek M., Zadak Z. DNA crosslinks, DNA damage and repair in peripheral blood lymphocytes of non-small cell lung cancer patients treated with platinum derivatives. Oncol Rep. 2014; 31(1): 391–6. doi: 10.3892/or.2013.2805.Allione A., Pardini B., Viberti C., Oderda M., Allasia M., Gontero P., Vineis P., Sacerdote C., Matullo G. The prognostic value of basal DNA damage level in peripheral blood lymphocytes of patients afected by bladder cancer. Urol Oncol. 2018; 36(5). doi: 10.1016/j. urolonc.2018.01.006.Allione A., Pardini B., Viberti C., Oderda M., Allasia M., Gontero P., Vineis P., Sacerdote C., Matullo G. The prognostic value of basal DNA damage level in peripheral blood lymphocytes of patients afected by bladder cancer. Urol Oncol. 2018; 36(5). doi: 10.1016/j. urolonc.2018.01.006.Sestakova Z., Kalavska K., Smolkova B., Miskovska V., Rejlekova K., Sycova-Mila Z., Palacka P., Obertova J., Holickova A., Hurbanova L., Jurkovicova D., Roska J., Goffa E., Svetlovska D., Chovanec M., Mardiak J., Mego M., Chovanec M. DNA damage measured in blood cells predicts overall and progression-free survival in germ cell tumour patients. Mutat Res Genet Toxicol Environ Mutagen. 2020. doi: 10.1016/j. mrgentox.2020.503200.Sestakova Z., Kalavska K., Smolkova B., Miskovska V., Rejlekova K., Sycova-Mila Z., Palacka P., Obertova J., Holickova A., Hurbanova L., Jurkovicova D., Roska J., Goffa E., Svetlovska D., Chovanec M., Mardiak J., Mego M., Chovanec M. DNA damage measured in blood cells predicts overall and progression-free survival in germ cell tumour patients. Mutat Res Genet Toxicol Environ Mutagen. 2020. doi: 10.1016/j. mrgentox.2020.503200.Bonassi S., Ceppi M., Møller P., Azqueta A., Milić M., Neri M., Brunborg G., Godschalk R., Koppen G., Langie S.A.S., Teixeira J.P., Bruzzone M., Da Silva J., Benedetti D., Cavallo D., Ursini C.L., Giovannelli L., Moretti S., Riso P., Del Bo’ C., Russo P., Dobrzyńska M., Goroshinskaya I.A., Surikova E.I., Staruchova M., Barančokova M., Volkovova K., Kažimirova A., Smolkova B., Laffon B., Valdiglesias V., Pastor S., Marcos R., Hernández A., Gajski G., Spremo-Potparević B., Živković L., BoutetRobinet E., Perdry H., Lebailly P., Perez C.L., Basaran N., Nemeth Z., Safar A., Dusinska M., Collins A.; hCOMET project. DNA damage in circulating leukocytes measured with the comet assay may predict the risk of death. Sci Rep. 2021; 11(1): 16793. doi: 10.1038/s41598-021-95976-7.Bonassi S., Ceppi M., Møller P., Azqueta A., Milić M., Neri M., Brunborg G., Godschalk R., Koppen G., Langie S.A.S., Teixeira J.P., Bruzzone M., Da Silva J., Benedetti D., Cavallo D., Ursini C.L., Giovannelli L., Moretti S., Riso P., Del Bo’ C., Russo P., Dobrzyńska M., Goroshinskaya I.A., Surikova E.I., Staruchova M., Barančokova M., Volkovova K., Kažimirova A., Smolkova B., Laffon B., Valdiglesias V., Pastor S., Marcos R., Hernández A., Gajski G., Spremo-Potparević B., Živković L., BoutetRobinet E., Perdry H., Lebailly P., Perez C.L., Basaran N., Nemeth Z., Safar A., Dusinska M., Collins A.; hCOMET project. DNA damage in circulating leukocytes measured with the comet assay may predict the risk of death. Sci Rep. 2021; 11(1): 16793. doi: 10.1038/s41598-021-95976-7.Loumaye A., Thissen J.P. Biomarkers of cancer cachexia. Clin Biochem. 2017; 50(18): 1281–8. doi: 10.1016/j.clinbiochem.2017.07.011.Loumaye A., Thissen J.P. Biomarkers of cancer cachexia. Clin Biochem. 2017; 50(18): 1281–8. doi: 10.1016/j.clinbiochem.2017.07.011.Chesnokova V., Melmed S. Peptide Hormone Regulation of DNA Damage Responses Endocr Rev. 2020; 41(4): 519–37. doi: 10.1210/ endrev/bnaa009.Chesnokova V., Melmed S. Peptide Hormone Regulation of DNA Damage Responses Endocr Rev. 2020; 41(4): 519–37. doi: 10.1210/ endrev/bnaa009.Argilés J.M., Busquets S., Stemmler B., López-Soriano F.J. Cancer cachexia: understanding the molecular basis. Nat Rev Cancer. 2014; 14(11): 754–62. doi: 10.1038/nrc3829.Argilés J.M., Busquets S., Stemmler B., López-Soriano F.J. Cancer cachexia: understanding the molecular basis. Nat Rev Cancer. 2014; 14(11): 754–62. doi: 10.1038/nrc3829.Wan G., Mathur R., Hu X., Zhang X., Lu X. miRNA response to DNA damage. Trends Biochem Sci. 2011; 36(9): 478–84. doi: 10.1016/j. tibs.2011.06.002.Wan G., Mathur R., Hu X., Zhang X., Lu X. miRNA response to DNA damage. Trends Biochem Sci. 2011; 36(9): 478–84. doi: 10.1016/j. tibs.2011.06.002.Visser H., Thomas A.D. MicroRNAs, damage levels, and DNA damage response control. Trends Genet. 2021; 37(11): 963–5. doi: 10.1016/j.tig.2021.06.018.Visser H., Thomas A.D. MicroRNAs, damage levels, and DNA damage response control. Trends Genet. 2021; 37(11): 963–5. doi: 10.1016/j.tig.2021.06.018.Yang C., Xia Z., Zhu L., Li Y., Zheng Z., Liang J., Wu L. MicroRNA139-5p modulates the growth and metastasis of malignant melanoma cells via the PI3K/AKT signaling pathway by binding to IGF1R. Cell Cycle. 2019; 18(24): 3513–24. doi: 10.1080/15384101.2019.1690881.Yang C., Xia Z., Zhu L., Li Y., Zheng Z., Liang J., Wu L. MicroRNA139-5p modulates the growth and metastasis of malignant melanoma cells via the PI3K/AKT signaling pathway by binding to IGF1R. Cell Cycle. 2019; 18(24): 3513–24. doi: 10.1080/15384101.2019.1690881.Chung I.M., Rajakumar G., Venkidasamy B., Subramanian U., Thiruvengadam M. Exosomes: Current use and future applications. Clin Chim Acta. 2020; 500: 226–32. doi: 10.1016/j.cca.2019.10.022.Chung I.M., Rajakumar G., Venkidasamy B., Subramanian U., Thiruvengadam M. Exosomes: Current use and future applications. Clin Chim Acta. 2020; 500: 226–32. doi: 10.1016/j.cca.2019.10.022.Gowda R., Robertson B.M., Iyer S., Barry J., Dinavahi S.S., Robertson G.P. The role of exosomes in metastasis and progression of melanoma. Cancer Treat Rev. 2020; 85. doi: 10.1016/j.ctrv.2020.101975.Gowda R., Robertson B.M., Iyer S., Barry J., Dinavahi S.S., Robertson G.P. The role of exosomes in metastasis and progression of melanoma. Cancer Treat Rev. 2020; 85. doi: 10.1016/j.ctrv.2020.101975.Khan A.Q., Akhtar S., Prabhu K.S., Zarif L., Khan R., Alam M., Buddenkotte J., Ahmad A., Steinhoff M., Uddin S. Exosomes: Emerging Diagnostic and Therapeutic Targets in Cutaneous Diseases. Int J Mol Sci. 2020; 21(23): 9264. doi: 10.3390/ijms21239264.Khan A.Q., Akhtar S., Prabhu K.S., Zarif L., Khan R., Alam M., Buddenkotte J., Ahmad A., Steinhoff M., Uddin S. Exosomes: Emerging Diagnostic and Therapeutic Targets in Cutaneous Diseases. Int J Mol Sci. 2020; 21(23): 9264. doi: 10.3390/ijms21239264.Цырлина Е.В., Порошина Т.Е., Оганесян А.П., Проценко С.А., Берштейн Л.М. Повреждение ДНК мононуклеарных клеток периферической крови, выявленное методом «комет», как возможный показатель чувствительности меланомы к иммунотерапии ниволумабом. Сибирский онкологический журнал. 2021; 20(2): 37–45. [Tsyrlina E.V., Poroshina T.E., Oganesyan A.P., Protsenko S.A., Bershtein L.M. Peripheral blood mononuclear dna damage identifed by the «сomet» method, as a possible indicator of sensitivity of melanoma to immunotherapy with nivolumab. Siberian Journal of Oncology. 2021; 20(2): 37–45. (in Russian)]. doi: 10.21294/1814-4861-2021-20-2-37-45.Цырлина Е.В., Порошина Т.Е., Оганесян А.П., Проценко С.А., Берштейн Л.М. Повреждение ДНК мононуклеарных клеток периферической крови, выявленное методом «комет», как возможный показатель чувствительности меланомы к иммунотерапии ниволумабом. Сибирский онкологический журнал. 2021; 20(2): 37–45. [Tsyrlina E.V., Poroshina T.E., Oganesyan A.P., Protsenko S.A., Bershtein L.M. Peripheral blood mononuclear dna damage identifed by the «сomet» method, as a possible indicator of sensitivity of melanoma to immunotherapy with nivolumab. Siberian Journal of Oncology. 2021; 20(2): 37–45. (in Russian)]. doi: 10.21294/1814-4861-2021-20-2-37-45.McKelvey-Martin V.J., Green M.H., Schmezer P., Pool-Zobel B.L., De Méo M.P., Collins A. The single cell gel electrophoresis assay (comet assay): a European review. Mutat Res. 1993; 288(1): 47–63. doi: 10.1016/0027-5107(93)90207-v.McKelvey-Martin V.J., Green M.H., Schmezer P., Pool-Zobel B.L., De Méo M.P., Collins A. The single cell gel electrophoresis assay (comet assay): a European review. Mutat Res. 1993; 288(1): 47–63. doi: 10.1016/0027-5107(93)90207-v.Milic M., Frustaci A., Del Bufalo A., Sánchez-Alarcón J., ValenciaQuintana R., Russo P., Bonassi S. DNA damage in non-communicable diseases: A clinical and epidemiological perspective. Mutat Res. 2015; 776: 118–27. doi: 10.1016/j.mrfmmm.2014.11.009.Milic M., Frustaci A., Del Bufalo A., Sánchez-Alarcón J., ValenciaQuintana R., Russo P., Bonassi S. DNA damage in non-communicable diseases: A clinical and epidemiological perspective. Mutat Res. 2015; 776: 118–27. doi: 10.1016/j.mrfmmm.2014.11.009.Møller P. Measurement of oxidatively damaged DNA in mammalian cells using the comet assay: Refections on validity, reliability and variability. Mutat Res Genet Toxicol Environ Mutagen. 2022; 873. doi: 10.1016/j.mrgentox.2021.503423.Møller P. Measurement of oxidatively damaged DNA in mammalian cells using the comet assay: Refections on validity, reliability and variability. Mutat Res Genet Toxicol Environ Mutagen. 2022; 873. doi: 10.1016/j.mrgentox.2021.503423.Voinea S., Blidaru A., Panaitescu E., Sandru A. Impact of gender and primary tumor location on outcome of patients with cutaneous melanoma. J Med Life. 2016; 9(4): 444–8.Voinea S., Blidaru A., Panaitescu E., Sandru A. Impact of gender and primary tumor location on outcome of patients with cutaneous melanoma. J Med Life. 2016; 9(4): 444–8.Shimizu I., Yoshida Y., Suda M., Minamino T. DNA damage response and metabolic disease. Cell Metab. 2014; 20(6): 967–77. doi: 10.1016/j.cmet.2014.10.008.Shimizu I., Yoshida Y., Suda M., Minamino T. DNA damage response and metabolic disease. Cell Metab. 2014; 20(6): 967–77. doi: 10.1016/j.cmet.2014.10.008.Vodicka P., Vodenkova S., Opattova A., Vodickova L. DNA damage and repair measured by comet assay in cancer patients. Mutat Res Genet Toxicol Environ Mutagen. 2019; 843: 95–110. doi: 10.1016/j. mrgentox.2019.05.009.Vodicka P., Vodenkova S., Opattova A., Vodickova L. DNA damage and repair measured by comet assay in cancer patients. Mutat Res Genet Toxicol Environ Mutagen. 2019; 843: 95–110. doi: 10.1016/j. mrgentox.2019.05.009.Snyder A., Makarov V., Merghoub T., Yuan J., Zaretsky J.M., Desrichard A., Walsh L.A., Postow M.A., Wong P., Ho T.S., Hollmann T.J., Bruggeman C., Kannan K., Li Y., Elipenahli C., Liu C., Harbison C.T., Wang L., Ribas A., Wolchok J.D., Chan T.A. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014; 371(23): 2189–99. doi: 10.1056/NEJMoa1406498.Snyder A., Makarov V., Merghoub T., Yuan J., Zaretsky J.M., Desrichard A., Walsh L.A., Postow M.A., Wong P., Ho T.S., Hollmann T.J., Bruggeman C., Kannan K., Li Y., Elipenahli C., Liu C., Harbison C.T., Wang L., Ribas A., Wolchok J.D., Chan T.A. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014; 371(23): 2189–99. doi: 10.1056/NEJMoa1406498.

The authors declare that there are no conflicts of interest present.